TSXV:KHRN.H - Post by User
Comment by
zardoz00on Mar 04, 2021 10:44am
![](https://assets.stockhouse.com/kentico-cms/0338-00/images/Sprite.svg#id_Post_Views_Icon)
136 Views
Post# 32714566
RE:Khiron newsletter Mar 4 2021
RE:Khiron newsletter Mar 4 2021Excerpt from the newsletter:
- Khiron has issued over 10,000 medical cannabis paid prescriptions and reports a significant increase in written prescriptions since the inclusion of the company’s products and services under health insurance policies in Colombia.
- On a per-capita basis, the company’s patient volumes in Bogota put Khiron in line with countries like Canada and Germany and its initial growth rates exceed industry leaders like Trulieve back in 2017.
- In the global context, Khiron’s retail prices remain very strong, currently in the CAD 50-60/unit range, which is above or on par with average tincture prices in markets like Canada.
- The company has achieved a 50% compound monthly growth in paid prescriptions since April last year.
- By being vertically integrated, with four wholly-owned clinics and high-quality cultivation and extraction assets, Khiron is generating industry-leading margins, currently over 80%.
- 92% of the company’s patients report an improvement in their primary condition after four months of treatment.
- During the last 2 months, Khiron had made almost 50% of the total written medical cannabis prescriptions done in 2020.